PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 001D55

Summary of knowledge gaps related to quality and efficacy of current influenza vaccines

Identifieur interne : 001D55 ( PascalFrancis/Curation ); précédent : 001D54; suivant : 001D56

Summary of knowledge gaps related to quality and efficacy of current influenza vaccines

Auteurs : Michael Pfleiderer [Allemagne] ; Jean-Hugues Trouvin [France] ; Daniel Brasseur [Belgique] ; Marta Gr Nstrom [Suède] ; Ragini Shivji [Royaume-Uni] ; Manuela Mura [Royaume-Uni] ; Marco Cavaleri [Royaume-Uni]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0190716

Descripteurs français

Pascal (Inist)
- Efficacité, Vaccin, Vaccination, Sérologie, Grippe.
Wicri :
- topic : Vaccin, Vaccination.

English descriptors

KwdEn :
- Efficiency, Influenza, Serology, Vaccination, Vaccine.

Abstract

Influenza viruses are a public health threat, as they are pathogenic, highly transmissible and prone to genetic changes. For decades vaccination strategies have been based on trivalent inactivated vaccines, which are regulated by specific guidelines. The progress in scientific knowledge and the lessons learned from the A(H1N1)2009 pandemic have highlighted further the need to improve current guidelines, including the immunogenicity criteria set by the CHMP in 1997, and to promote the discussion on the shortcomings encountered, e.g. the evaluation of vaccine efficacy in the paediatric and elderly populations, the measurement of the naivety of a population, the impact of prior immunity on subsequent vaccinations, and the technical issues with the serological assays for detection of immunity and immunogenicity. The authors attempted to summarise and tackle key gaps in the existing evidence concerning quality and efficacy of influenza vaccines, aiming at favouring a common understanding and a coordinated approach across stakeholders.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 35`
A08	`01`	`1`	`ENG`	`@1 Summary of knowledge gaps related to quality and efficacy of current influenza vaccines`
A11	`01`	`1`		`@1 PFLEIDERER (Michael)`
A11	`02`	`1`		`@1 TROUVIN (Jean-Hugues)`
A11	`03`	`1`		`@1 BRASSEUR (Daniel)`
A11	`04`	`1`		`@1 GRÄNSTROM (Marta)`
A11	`05`	`1`		`@1 SHIVJI (Ragini)`
A11	`06`	`1`		`@1 MURA (Manuela)`
A11	`07`	`1`		`@1 CAVALERI (Marco)`
A14	`01`			`@1 Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) @3 EUR @Z 1 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59 @2 63225 Langen @3 DEU @Z 1 aut.`
A14	`03`			`@1 Paris Descartes University, School of Pharmacy, Health Safety and Public Health Department @2 Paris @3 FRA @Z 2 aut.`
A14	`04`			`@1 Agence Fédérale des Medicaments et des Produits de Santé, Batiment EUROSTATION, bloc 2, place Victor Horta, 40/40 @2 1060 Brussels @3 BEL @Z 3 aut.`
A14	`05`			`@1 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) @3 EUR @Z 3 aut.`
A14	`06`			`@1 MTC, Karolinska Institutet @2 Stockholm @3 SWE @Z 4 aut.`
A14	`07`			`@1 Paediatric Committee of the European Medicines Agency (EMA) @3 EUR @Z 4 aut.`
A14	`08`			`@1 European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf @2 London E14 4HB @3 GBR @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 4586-4591`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000150336410320`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 14-0190716`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Influenza viruses are a public health threat, as they are pathogenic, highly transmissible and prone to genetic changes. For decades vaccination strategies have been based on trivalent inactivated vaccines, which are regulated by specific guidelines. The progress in scientific knowledge and the lessons learned from the A(H1N1)2009 pandemic have highlighted further the need to improve current guidelines, including the immunogenicity criteria set by the CHMP in 1997, and to promote the discussion on the shortcomings encountered, e.g. the evaluation of vaccine efficacy in the paediatric and elderly populations, the measurement of the naivety of a population, the impact of prior immunity on subsequent vaccinations, and the technical issues with the serological assays for detection of immunity and immunogenicity. The authors attempted to summarise and tackle key gaps in the existing evidence concerning quality and efficacy of influenza vaccines, aiming at favouring a common understanding and a coordinated approach across stakeholders.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Efficacité @5 05`
C03	`01`	`X`	`ENG`	`@0 Efficiency @5 05`
C03	`01`	`X`	`SPA`	`@0 Eficacia @5 05`
C03	`02`	`X`	`FRE`	`@0 Vaccin @5 06`
C03	`02`	`X`	`ENG`	`@0 Vaccine @5 06`
C03	`02`	`X`	`SPA`	`@0 Vacuna @5 06`
C03	`03`	`X`	`FRE`	`@0 Vaccination @5 07`
C03	`03`	`X`	`ENG`	`@0 Vaccination @5 07`
C03	`03`	`X`	`SPA`	`@0 Vacunación @5 07`
C03	`04`	`X`	`FRE`	`@0 Sérologie @5 08`
C03	`04`	`X`	`ENG`	`@0 Serology @5 08`
C03	`04`	`X`	`SPA`	`@0 Serología @5 08`
C03	`05`	`X`	`FRE`	`@0 Grippe @5 14`
C03	`05`	`X`	`ENG`	`@0 Influenza @5 14`
C03	`05`	`X`	`SPA`	`@0 Gripe @5 14`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
N21				`@1 237`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000064

Links to Exploration step

Pascal:14-0190716

Curation

No country items

Michael Pfleiderer

<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59</s1>
<s2>63225 Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>

Daniel Brasseur

<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Agence Fédérale des Medicaments et des Produits de Santé, Batiment EUROSTATION, bloc 2, place Victor Horta, 40/40</s1>
<s2>1060 Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>

<affiliation><inist:fA14 i1="05"><s1>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

Daniel Brasseur

<affiliation><inist:fA14 i1="05"><s1>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

Marta Gr Nstrom

<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>MTC, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>

<affiliation><inist:fA14 i1="07"><s1>Paediatric Committee of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

Marta Gr Nstrom

<affiliation><inist:fA14 i1="07"><s1>Paediatric Committee of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Summary of knowledge gaps related to quality and efficacy of current influenza vaccines</title>
<author><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59</s1>
<s2>63225 Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Trouvin, Jean Hugues" sort="Trouvin, Jean Hugues" uniqKey="Trouvin J" first="Jean-Hugues" last="Trouvin">Jean-Hugues Trouvin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University, School of Pharmacy, Health Safety and Public Health Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brasseur, Daniel" sort="Brasseur, Daniel" uniqKey="Brasseur D" first="Daniel" last="Brasseur">Daniel Brasseur</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Agence Fédérale des Medicaments et des Produits de Santé, Batiment EUROSTATION, bloc 2, place Victor Horta, 40/40</s1>
<s2>1060 Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gr Nstrom, Marta" sort="Gr Nstrom, Marta" uniqKey="Gr Nstrom M" first="Marta" last="Gr Nstrom">Marta Gr Nstrom</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>MTC, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Paediatric Committee of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Shivji, Ragini" sort="Shivji, Ragini" uniqKey="Shivji R" first="Ragini" last="Shivji">Ragini Shivji</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Mura, Manuela" sort="Mura, Manuela" uniqKey="Mura M" first="Manuela" last="Mura">Manuela Mura</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Cavaleri, Marco" sort="Cavaleri, Marco" uniqKey="Cavaleri M" first="Marco" last="Cavaleri">Marco Cavaleri</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0190716</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0190716 INIST</idno>
<idno type="RBID">Pascal:14-0190716</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000064</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Summary of knowledge gaps related to quality and efficacy of current influenza vaccines</title>
<author><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59</s1>
<s2>63225 Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Trouvin, Jean Hugues" sort="Trouvin, Jean Hugues" uniqKey="Trouvin J" first="Jean-Hugues" last="Trouvin">Jean-Hugues Trouvin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University, School of Pharmacy, Health Safety and Public Health Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brasseur, Daniel" sort="Brasseur, Daniel" uniqKey="Brasseur D" first="Daniel" last="Brasseur">Daniel Brasseur</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Agence Fédérale des Medicaments et des Produits de Santé, Batiment EUROSTATION, bloc 2, place Victor Horta, 40/40</s1>
<s2>1060 Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gr Nstrom, Marta" sort="Gr Nstrom, Marta" uniqKey="Gr Nstrom M" first="Marta" last="Gr Nstrom">Marta Gr Nstrom</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>MTC, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Paediatric Committee of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<wicri:noCountry>EUR</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Shivji, Ragini" sort="Shivji, Ragini" uniqKey="Shivji R" first="Ragini" last="Shivji">Ragini Shivji</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Mura, Manuela" sort="Mura, Manuela" uniqKey="Mura M" first="Manuela" last="Mura">Manuela Mura</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Cavaleri, Marco" sort="Cavaleri, Marco" uniqKey="Cavaleri M" first="Marco" last="Cavaleri">Marco Cavaleri</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Efficiency</term>
<term>Influenza</term>
<term>Serology</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Efficacité</term>
<term>Vaccin</term>
<term>Vaccination</term>
<term>Sérologie</term>
<term>Grippe</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza viruses are a public health threat, as they are pathogenic, highly transmissible and prone to genetic changes. For decades vaccination strategies have been based on trivalent inactivated vaccines, which are regulated by specific guidelines. The progress in scientific knowledge and the lessons learned from the A(H1N1)2009 pandemic have highlighted further the need to improve current guidelines, including the immunogenicity criteria set by the CHMP in 1997, and to promote the discussion on the shortcomings encountered, e.g. the evaluation of vaccine efficacy in the paediatric and elderly populations, the measurement of the naivety of a population, the impact of prior immunity on subsequent vaccinations, and the technical issues with the serological assays for detection of immunity and immunogenicity. The authors attempted to summarise and tackle key gaps in the existing evidence concerning quality and efficacy of influenza vaccines, aiming at favouring a common understanding and a coordinated approach across stakeholders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>35</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Summary of knowledge gaps related to quality and efficacy of current influenza vaccines</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PFLEIDERER (Michael)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TROUVIN (Jean-Hugues)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BRASSEUR (Daniel)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GRÄNSTROM (Marta)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SHIVJI (Ragini)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MURA (Manuela)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CAVALERI (Marco)</s1>
</fA11>
<fA14 i1="01"><s1>Vaccine Working Party of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59</s1>
<s2>63225 Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Paris Descartes University, School of Pharmacy, Health Safety and Public Health Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Agence Fédérale des Medicaments et des Produits de Santé, Batiment EUROSTATION, bloc 2, place Victor Horta, 40/40</s1>
<s2>1060 Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>MTC, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Paediatric Committee of the European Medicines Agency (EMA)</s1>
<s3>EUR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf</s1>
<s2>London E14 4HB</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>4586-4591</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000150336410320</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0190716</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Influenza viruses are a public health threat, as they are pathogenic, highly transmissible and prone to genetic changes. For decades vaccination strategies have been based on trivalent inactivated vaccines, which are regulated by specific guidelines. The progress in scientific knowledge and the lessons learned from the A(H1N1)2009 pandemic have highlighted further the need to improve current guidelines, including the immunogenicity criteria set by the CHMP in 1997, and to promote the discussion on the shortcomings encountered, e.g. the evaluation of vaccine efficacy in the paediatric and elderly populations, the measurement of the naivety of a population, the impact of prior immunity on subsequent vaccinations, and the technical issues with the serological assays for detection of immunity and immunogenicity. The authors attempted to summarise and tackle key gaps in the existing evidence concerning quality and efficacy of influenza vaccines, aiming at favouring a common understanding and a coordinated approach across stakeholders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Efficacité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Efficiency</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Eficacia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sérologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Serology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Serología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Grippe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Influenza</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Gripe</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>237</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0190716
   |texte=   Summary of knowledge gaps related to quality and efficacy of current influenza vaccines
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Summary of knowledge gaps related to quality and efficacy of current influenza vaccines

Summary of knowledge gaps related to quality and efficacy of current influenza vaccines

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri